Equities analysts expect that Endologix, Inc. (NASDAQ:ELGX) will post $45.37 million in sales for the current quarter, according to Zacks. Four analysts have made estimates for Endologix’s earnings, with the lowest sales estimate coming in at $44.00 million and the highest estimate coming in at $46.16 million. Endologix posted sales of $47.46 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 4.4%. The company is scheduled to announce its next quarterly earnings report on Wednesday, February 28th.
According to Zacks, analysts expect that Endologix will report full-year sales of $45.37 million for the current year, with estimates ranging from $181.10 million to $183.31 million. For the next year, analysts anticipate that the firm will post sales of $187.73 million per share, with estimates ranging from $183.60 million to $191.20 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that cover Endologix.
Several analysts have recently weighed in on the company. Piper Jaffray Companies restated an “overweight” rating on shares of Endologix in a research note on Tuesday. Royal Bank of Canada lowered their target price on Endologix from $5.00 to $4.00 and set a “sector perform” rating for the company in a research note on Wednesday, November 8th. Canaccord Genuity restated a “hold” rating and set a $5.00 target price on shares of Endologix in a research note on Monday, October 9th. Stifel Nicolaus set a $6.00 target price on Endologix and gave the company a “hold” rating in a research note on Friday, October 6th. Finally, ValuEngine downgraded Endologix from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and one has assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $5.41.
Large investors have recently bought and sold shares of the stock. Alliancebernstein L.P. grew its stake in Endologix by 11.5% in the second quarter. Alliancebernstein L.P. now owns 108,757 shares of the medical instruments supplier’s stock worth $529,000 after purchasing an additional 11,200 shares in the last quarter. Swiss National Bank grew its stake in Endologix by 14.3% in the second quarter. Swiss National Bank now owns 137,900 shares of the medical instruments supplier’s stock worth $670,000 after purchasing an additional 17,300 shares in the last quarter. Schwab Charles Investment Management Inc. grew its stake in Endologix by 10.5% in the second quarter. Schwab Charles Investment Management Inc. now owns 321,309 shares of the medical instruments supplier’s stock worth $1,562,000 after purchasing an additional 30,429 shares in the last quarter. Teachers Advisors LLC grew its stake in Endologix by 40.8% in the second quarter. Teachers Advisors LLC now owns 198,912 shares of the medical instruments supplier’s stock worth $967,000 after purchasing an additional 57,675 shares in the last quarter. Finally, Stephens Inc. AR grew its stake in Endologix by 10.5% in the second quarter. Stephens Inc. AR now owns 845,016 shares of the medical instruments supplier’s stock worth $4,107,000 after purchasing an additional 80,328 shares in the last quarter.
COPYRIGHT VIOLATION NOTICE: “Zacks: Brokerages Expect Endologix, Inc. (ELGX) Will Announce Quarterly Sales of $45.37 Million” was first posted by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.com-unik.info/2017/12/13/zacks-brokerages-expect-endologix-inc-elgx-will-announce-quarterly-sales-of-45-37-million.html.
Endologix Company Profile
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.